Test Price
600 AED✅ Home Collection Available
TEL/AML1 Qualitative Test in UAE | 600 AED | DHA-Licensed Molecular Diagnostics
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity through ISO-accredited Real-Time PCR (qPCR). Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Post-test clinical guidance by DHA-licensed specialists. Direct insurance billing verification via WhatsApp +971 54 548 8731. Results in 3–4 days.
Test Overview & Methodology
The TEL/AML1 (ETV6-RUNX1) Qualitative Test detects the most common fusion gene in childhood B-cell acute lymphoblastic leukemia (ALL) using Real-Time PCR (qPCR). This RNA-based molecular assay identifies the ETV6-RUNX1 fusion transcript with ultra-high sensitivity, enabling accurate diagnosis, precise risk stratification, and robust minimal residual disease (MRD) monitoring. Processed under ISO 9001:2015-accredited protocols with a 3–4 day turnaround, this test delivers the clinical clarity essential for timely, DHA-compliant therapeutic decisions in pediatric and adult hematology-oncology practice.
| Parameter | Our Test (Real-Time PCR) | FISH / Karyotyping |
|---|---|---|
| Detection Sensitivity | 1 abnormal cell in 1,000–10,000 | Typically 1–5% abnormal cells |
| Methodology | Real-Time PCR (qPCR) – RNA-based detection of fusion transcript | Fluorescence in situ hybridization (DNA-level) or conventional karyotyping |
| Turnaround Time | 3–4 days | 7–14 days (karyotyping); 3–5 days (FISH) |
| Clinical Actionability | Essential for MRD monitoring and treatment stratification | Primarily diagnostic; less suitable for MRD |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA Registration ID: 9294403 | Consultant Medical Genetics) states: "A positive TEL/AML1 result provides a powerful molecular biomarker for B-cell acute lymphoblastic leukemia, yet interpretation demands integration with complete blood counts, immunophenotyping, cytogenetic findings, and the full clinical history. This test is indispensable for risk-adjusted therapy and MRD surveillance, but real-world treatment decisions require expert multidisciplinary correlation. Patients must never alter or discontinue prescribed therapy based solely on a molecular test result without direct consultation with their treating hematologist-oncologist."
Advisory Notice – Medication and Treatment Continuity
Critical Safety Advisory
⚠️ Do not discontinue any prescribed chemotherapy, targeted therapy, supportive medication, or clinical trial intervention based solely on this test result. Any modification to an active treatment regimen must be made exclusively by your DHA-licensed specialist following a comprehensive clinical evaluation. Always carry your current medication list and test reports to every medical appointment.
Exclusion Criteria & Emergency Indicators
Safety Exclusion Criteria and Red Flags
- Active severe bleeding disorder or uncontrolled coagulopathy – sample collection may be deferred until hematological stability is confirmed.
- Inability to provide a valid DHA-issued prescription from a licensed physician (mandatory for test initiation per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Age below 18 years without documented legal guardian consent, in accordance with UAE medical liability statutes governing pediatric procedures.
- Emergency Red Flags: New sudden onset bone pain, unexplained persistent fever exceeding 38.5°C, easy bruising, petechiae, or pallor in the context of suspected acute leukemia – seek immediate emergency medical care; do not await test results.
Patient FAQ & Clinical Guidance
1. What is the TEL/AML1 fusion gene and why is this test ordered?
The TEL/AML1 Qualitative test detects the ETV6-RUNX1 fusion gene, the most common genetic alteration in childhood B-cell acute lymphoblastic leukemia (ALL). This biomarker guides diagnosis, risk classification, and minimal residual disease monitoring. The test requires either a bone marrow aspirate or peripheral blood sample collected under sterile hospital conditions. Results enable oncologists to tailor treatment intensity and determine appropriate long-term surveillance protocols.
2. Does this test require fasting or special preparation?
No fasting or dietary preparation is required. However, a valid DHA-licensed physician prescription is mandatory before sample collection. Inform your healthcare team about all current medications, including over-the-counter supplements and herbal products. Never pause or adjust any prescribed treatment without direct instruction from your managing specialist. Sample collection occurs exclusively within an accredited hospital environment following strict aseptic protocols.
3. When will I receive results and will insurance cover the cost?
Your ISO-accredited laboratory delivers final reports within 3–4 days from sample receipt. Direct insurance billing verification is available instantly via WhatsApp at +971 54 548 8731 – simply forward your Emirates ID and insurance policy details. The test is priced at 600 AED and is typically covered by major UAE health insurance plans when ordered for clinically indicated ALL evaluation. A secure digital report is provided, with optional tele-consultation for professional result interpretation by our genetics team.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data are encrypted, access-controlled, and processed exclusively within UAE jurisdiction. Clinical testing safety and patient consent procedures adhere strictly to Federal Decree-Law No. 4 of 2016 on Medical Liability. A valid prescription from a DHA-licensed physician is mandatory for test initiation. Samples are processed in an ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited laboratory. Your privacy and data security are our highest priority.
Clinical & Logistical Metadata
| Test Name | TEL/AML1 (ETV6-RUNX1) Qualitative Test – Real-Time PCR |
| Price (AED) | 600 AED |
| Turnaround Time | 3–4 days |
| Sample Type / Matrix | Bone Marrow Aspirate or Peripheral Blood – Hospital Extraction Only |
| Methodology Used | Real-Time Quantitative PCR (qPCR) – RNA-based fusion transcript detection |
| ICD-10-CM Code | C91.0 |
| LOINC Code | 49797-6 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians